Myelodysplastic Neoplasms/Syndromes (MDS)-Reference-Cited by-同舟云学术

Myelodysplastic Neoplasms/Syndromes (MDS)

Published:2024 Issue: Volume: Page:669-677
ISSN:
Container-title:The EBMT Handbook
language:en
Short-container-title:

Author:

Robin Marie,Gurnari Carmelo

Abstract

AbstractMyelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of clonal stem cell disorders characterized by peripheral cytopenias and dysplastic features in blood and bone marrow.

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-031-44080-9_74

Reference34 articles.

1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, Wang SA, et al. International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–28. https://doi.org/10.1182/blood.2022015850.

2. Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, et al. Myeloablative conditioning for allogeneic transplantation results in superior disease-free survival for acute myelogenous leukemia and myelodysplastic syndromes with low/intermediate but not high disease risk index: a center for international blood and marrow transplant research study. Transplant Cell Ther. 2021;27(1):68.e1–9. https://doi.org/10.1016/j.bbmt.2020.09.026.

3. Craddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, Bourhis JH, et al. Clinical activity of Azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2016;101(7):879–83. https://doi.org/10.3324/haematol.2015.140996.

4. Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, Andrew G, et al. Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute Myeloid Leukemia. J Clin Oncol. 2021;39(7):768–78. https://doi.org/10.1200/JCO.20.02308.

5. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, Bolwell BJ, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579–85.